What is the beta‑blocker of choice for a patient with rheumatic heart disease who has mitral stenosis and aortic regurgitation?

Beta-Blocker of Choice in RHD with MS and AR

For patients with rheumatic heart disease presenting with both mitral stenosis and aortic regurgitation, metoprolol is the beta-blocker of choice, as it effectively reduces heart rate and transmitral gradient without exacerbating the aortic regurgitation.

Rationale and Evidence

Primary Indication: Mitral Stenosis Management

The most critical therapeutic target in this combination is the mitral stenosis component. Beta-blockers are specifically recommended for heart rate control in patients with severe mitral stenosis 1. The American and European guidelines explicitly recommend beta-blockers to achieve reduced heart rate in patients with mitral stenosis in sinus rhythm 1.

The mechanism is straightforward: by slowing heart rate, beta-blockers prolong diastolic filling time, which reduces the transmitral pressure gradient and improves left ventricular filling. This is particularly crucial in mitral stenosis where the stenotic valve requires longer filling time to maintain adequate cardiac output 2.

Metoprolol: The Preferred Agent

Metoprolol specifically has demonstrated efficacy in reducing valve gradients and myocardial oxygen consumption 3. In the research literature, metoprolol has been the most studied beta-blocker in rheumatic mitral regurgitation, showing:

• Significant reduction in LV end-systolic and end-diastolic volumes (15.6% and 10.4% respectively)
• Decreased LV end-systolic stress by 15.6%
• Reduction in LV work by 28%
• Improved NYHA functional class 4

Addressing the Aortic Regurgitation Component

The concern with beta-blockers in aortic regurgitation is theoretical: bradycardia prolongs diastole, potentially increasing regurgitant volume 5, 3. However, this concern has not translated into clinical harm. A small randomized study showed metoprolol caused no adverse change in LV dimensions in patients with AR over 6 months compared to placebo 3. In fact, retrospective data suggests beta-blockers may increase survival in AR patients, though with increased need for eventual valve surgery 3.

Practical Implementation

Dosing Strategy

• Start low: Begin with metoprolol 25 mg twice daily
• Titrate gradually: Increase by 25 mg increments every 1-2 weeks
• Target dose: 37-50 mg twice daily (mean effective dose from RHD studies: 37±13.5 mg) 4
• Target heart rate: 60-70 bpm at rest, <100 bpm with activity

Monitoring Parameters

• Heart rate: Check resting and ambulatory rates
• Blood pressure: Avoid excessive hypotension (maintain SBP >100 mmHg)
• Symptoms: Assess dyspnea, exercise tolerance, NYHA class
• Echocardiography: Repeat at 3 months to assess:
  • Transmitral gradient
  • LV volumes and function
  • Pulmonary artery pressures
  • AR severity (should remain stable or improve)

Critical Caveats

Absolute Contraindications

• Severe bradycardia (<50 bpm) or high-degree AV block without pacemaker
• Decompensated heart failure with cardiogenic shock
• Severe hypotension (SBP <90 mmHg)
• Active bronchospasm or severe reactive airways disease

Relative Contraindications Requiring Caution

• Small LV cavity size (use lower doses)
• Severe LV dysfunction (EF <30%)
• Concurrent use of other negative chronotropes

When Beta-Blockers Are Insufficient

If heart rate control remains inadequate despite optimal beta-blocker therapy, consider adding ivabradine (specific If channel blocker) as recommended by guidelines for mitral stenosis 1. This provides additional rate control without negative inotropy.

Alternative Considerations

Bisoprolol or carvedilol are acceptable alternatives if the patient has concurrent heart failure with reduced ejection fraction, as these are the proven mortality-reducing beta-blockers in HF 6, 7. However, metoprolol remains preferred for pure valvular disease without systolic dysfunction.

Avoid atenolol in this population due to inferior outcomes in cardiovascular disease and lack of specific data in valvular heart disease.

The Bottom Line

The combination of MS and AR in rheumatic heart disease requires prioritizing heart rate control for the mitral stenosis while accepting that beta-blockers are safe and potentially beneficial even with concurrent AR. Metoprolol provides the best evidence base, with demonstrated reductions in valve gradients, LV remodeling parameters, and symptomatic improvement in rheumatic valve disease 4, 2. Start low, titrate slowly, and monitor closely for both efficacy and tolerability.